Clinical Trials Directory

Trials / Unknown

UnknownNCT00894569

Paclitaxel/Carboplatin With or Without Cetuximab in CUP

Open-Labeled, Randomized Multi-Center Phase II Study Evaluating the Efficacy and Safety of Paclitaxel/ Carboplatin With and Without Cetuximab as First-Line Treatment of Adeno- and Undifferentiated Carcinoma of Unknown Primary (CUP)

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Heidelberg University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether an addition of cetuximab to carboplatin/paclitaxel can improve efficacy in comparison to carboplatin/paclitaxel in patients with carcinoma of unknown-primary.

Detailed description

Carcinomas of unknown primary (CUP) account for approximately 2-5% of all cancer diagnoses. Except for some subsets with favorable prognosis, for most of these patients, treatment options are limited, and no standard first-line regimen has been identified. Standard therapy for patients with adeno- or undifferentiated CUP is Paclitaxel/Carboplatin, yielding response rates between 20-40%. In recent years, targeted therapies with inhibitors to EGFR, several tyrosine kinases, and VEGF have been shown to improve survival in different solid tumor entities. Cetuximab, a monoclonal antibody against the EGF receptor, has proved efficacy in combination with chemotherapy in patients with metastatic colorectal cancer, gastric cancer, squamous cell carcinoma of head and neck and non-small cell lung cancer (NSCLC). Because of these promising results it seems to be reasonable to examine the impact of adding cetuximab to standard chemotherapy with paclitaxel and carboplatin in patients with CUP.

Conditions

Interventions

TypeNameDescription
DRUGpaclitaxel/carboplatin6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
DRUGcetuximabcetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression

Timeline

Start date
2009-07-01
Primary completion
2010-07-01
Completion
2011-08-01
First posted
2009-05-07
Last updated
2009-05-14

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00894569. Inclusion in this directory is not an endorsement.